Results 181 to 190 of about 964,911 (327)

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

MANAGING THE COMPLEXITY OF THROMBOTIC AND BLEEDING RISKS: CASE REPORT OF FACTOR VII DEFICIENCY AND FACTOR V LEIDEN MUTATION IN A PATIENT WITH BI-VALVULAR ENDOCARDITIS UNDERGOING OPEN-HEART SURGERY

Tharun Shyam, Soe P Winn, Vallabh Shet, Saumya Nanda, Momna Noor, Vahagn Tamazyan, Palvi Singla Jindal, Kamlesh Kumar, Alina Zatsepina, Stephen Peeke, Mariya Astashkevich   +10 more
openalex   +2 more sources

Tumor mutational burden as a determinant of metastatic dissemination patterns

Molecular Oncology, EarlyView.
This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal, Andrea Moreno‐Manuel, Miguel Salvadó‐Pertierra, Cristina Santos‐Vivas, Rebeca Sanz‐Pamplona   +4 more
wiley   +1 more source

From the ER to the Golgi: Insights from the Study of Combined Factors V and VIII Deficiency [PDF]

, 1999
William C. Nichols, David Ginsburg
openalex   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Acquired Factor V Deficiency [PDF]

, 2020
openaire   +1 more source

Novel functional defect in factor V deficiency [PDF]

, 2003
William H. Kane
openalex   +1 more source

Molecular genetics of common variable immunodeficiency

, 2017
Bogaert, Delfien, De Baere, Elfride, Dullaers, Melissa, Haerynck, Filomeen   +3 more
core   +1 more source

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source

[Analysis of a pedigree with inherited factor V deficiency caused by compound heterozygous mutation]. [PDF]

Zhonghua Xue Ye Xue Za Zhi, 2021
Guo YL, Kong WZ, Wan Q, Zheng WJY, Xi JQ, Liu SQ, Wang MS, Jin YH.   +7 more
europepmc   +1 more source